
    
      A Multicenter, Randomized, Double-blind, Controlled Phase II Trial of Allogenic Adipose
      Tissue-Derived Mesenchymal Progenitor Cells (AlloJoinÂ®) Therapy for Knee Osteoarthritis.

      This is a multicenter, randomized, double-blinded, phase II clinical trial. Subjects who are
      with a clinical diagnosis of knee osteoarthritis cartilage defects and will be randomly
      distributed 1:1:1 to different group after signing the ICF and screening tests. Each group
      was treated for two cycles. The patients were followed up to 48 weeks after the first
      treatment.
    
  